- Home
- ZGN vs NVCR Comparison
ZGN vs NVCR Comparison
Compare ZGN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- NVCR
- Stock Information
- Founded
- ZGN 1910
- NVCR 2000
- Country
- ZGN Italy
- NVCR Jersey
- Employees
- ZGN N/A
- NVCR N/A
- Industry
- ZGN Apparel
- NVCR Medical/Dental Instruments
- Sector
- ZGN Consumer Discretionary
- NVCR Health Care
- Exchange
- ZGN Nasdaq
- NVCR Nasdaq
- Market Cap
- ZGN 2.2B
- NVCR 3.2B
- IPO Year
- ZGN N/A
- NVCR 2015
- Fundamental
- Price
- ZGN $8.02
- NVCR $29.99
- Analyst Decision
- ZGN Buy
- NVCR Buy
- Analyst Count
- ZGN 2
- NVCR 5
- Target Price
- ZGN $12.95
- NVCR $33.40
- AVG Volume (30 Days)
- ZGN 670.1K
- NVCR 1.1M
- Earning Date
- ZGN 09-18-2024
- NVCR 02-20-2025
- Dividend Yield
- ZGN 1.63%
- NVCR N/A
- EPS Growth
- ZGN 14.68
- NVCR N/A
- EPS
- ZGN 0.42
- NVCR N/A
- Revenue
- ZGN $2,101,802,207.00
- NVCR $577,738,000.00
- Revenue This Year
- ZGN $1.34
- NVCR $19.13
- Revenue Next Year
- ZGN $3.73
- NVCR $5.38
- P/E Ratio
- ZGN $19.79
- NVCR N/A
- Revenue Growth
- ZGN 17.68
- NVCR 14.63
- 52 Week Low
- ZGN $7.13
- NVCR $11.70
- 52 Week High
- ZGN $15.26
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- ZGN 42.99
- NVCR 58.14
- Support Level
- ZGN $8.12
- NVCR $29.62
- Resistance Level
- ZGN $8.87
- NVCR $32.06
- Average True Range (ATR)
- ZGN 0.31
- NVCR 1.80
- MACD
- ZGN -0.07
- NVCR -0.60
- Stochastic Oscillator
- ZGN 6.70
- NVCR 8.20
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. It operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment; and the Tom Ford Fashion segment. It generates the majority of its revenue from the Zegna segment.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.